Pemphigus Market Share

ID: MRFR/Pharma/5024-HCR

100 Pages

Rahul Gotadki

October 2025

Pemphigus Market Research Report Information By Type (Pemphigus Vulgaris and Others), by Diagnosis (Skin Peeling, Endoscopy, and Others), by Treatment (Corticosteroid, Biological Therapies, and Others), by End-Users (Hospitals and Others)– Forecast Till 2035

Single User

$ 4,950.0

Multiple License

$ 5,950.0

Enterprise User

$ 7,250.0

Summary Table of Contents Segmentation Download PDF

Market Share

Pemphigus Market Share Analysis

The Pemphigus market, a sector that is situated within dermatology and autoimmune disorders, has in place many strategic moves to attain competitive position as well as tackling the unique challenges of this autoimmune blistering disease. The central strategy is therapeutic innovation, where companies spend heavily on research and development to come up with advanced treatments for Pemphigus. These novel treatment options focus on enhancing patient’s lives, reducing side effects and better management of the disease. Companies therefore aim at introducing fresh solutions into the market so that they will be different from others and take advantage of large share of Pemphigus treatment market. Pricing strategies play a crucial role in determining market share positioning in the Pemphigus segment. Given the long-term nature of autoimmune diseases as well as need for long-term treatment, different pricing models are usually adopted by companies. Some may choose to have competitive pricing which makes their therapies more affordable by a broader population. On the other hand, others use value-based pricing where they highlight specific advantages or innovative qualities present in their lines of treatment compared to other medications used in addressing Pemphigus thus justifying higher costs imposed on them. It is important to find an equilibrium between affordability and perceived worthiness so that patients can still have access to viable treatments while providing support for R&D sustainability. Success in the Pemphigus market hinges on collaborations and partnerships. Such alliances are formed by firms so as to engage skin experts, people who deal with autoimmunity conditions together with research institutions helping them navigate through complexities surrounding development of pemphigus related treatments. Consequently, joint activities hasten clinical trials allowing improved production protocols; hence a strong distribution network is achieved making these firms key players in the pemphigus treatment market. Marketing and branding strategies influence significantly market share within this industry segment. They engage themselves into extensive marketing campaigns aimed at addressing advantages offered by their Pemphigus treatment, creating awareness among dermatologists and health care professionals and building trust in their safety and efficacy. Presence in the market is created by use of educational projects, online platforms and participation on dermatology conferences thus influencing market share in a competitive landscape. In terms of strategic considerations for companies aiming to consolidate their market share in the Pemphigus treatment sector, geographical expansion becomes important. Identifying regions with high prevalence rates of Pemphigus and designing strategies that are responsive to various regional healthcare needs become imperative. Customizing products, distribution channels and marketing approaches that are suitable for different cultural norms as well as regulatory frameworks enable effective entry into various parts of the world hence complete global presence. As such, continued investment in post-market surveillance systems, pharmacovigilance activities as well as patient support programs is crucial for retaining as well as increasing market share in pemphigus treatment market. Proactively monitoring safety and effectiveness of treatments together with extensive education programs for patients ultimately helps to build trust between health practitioners with this particular category of sufferers. This long-term dedication towards patient wellness guarantees company’s achievement within the marketplace; as this indicates corporate social responsibility irrespective whether they are pemphigus stakeholders or not.

1. Market Overview

2. Market Trends

3. Market Segment Insights

4. Key Players and Competitive Insights

5. Industry Developments

6. Market Segmentation

7. Report Scope

8. Market Highlights

9. FAQs

Customize Report

Certified Researchers

Market Summary

The Global Pemphigus Market is projected to grow from 1.67 USD Billion in 2024 to 4.0 USD Billion by 2035, reflecting a robust growth trajectory.

Key Market Trends & Highlights

Global Pemphigus Key Trends and Highlights

The market is expected to expand at a compound annual growth rate (CAGR) of 8.25 percent from 2025 to 2035.
By 2035, the market valuation is anticipated to reach 4.0 USD Billion, indicating substantial growth potential.
In 2024, the market is valued at 1.67 USD Billion, laying a strong foundation for future expansion.
Growing adoption of innovative treatment options due to increasing prevalence of pemphigus is a major market driver.

Market Size & Forecast

2024 Market Size	1.67 (USD Billion)
2035 Market Size	4.0 (USD Billion)
CAGR (2025-2035)	8.25%
Largest Regional Market Share in 2024	latin_america)

Major Players

Novartis Pharmaceuticals, Hoffmann-La Roche, Principia Biopharma, Inc, Argenx, Sanofi S.A., Pfizer Inc, Teligent Inc, GlaxoSmithKline LLC, Teva Pharmaceutical Industries

Market Trends

The Global Pemphigus Market is poised for growth as advancements in therapeutic options and increased awareness of autoimmune diseases drive demand for effective treatment solutions.

National Institutes of Health (NIH)

Pemphigus Market Market Drivers

Market Growth Projections

The Global Pemphigus Market Industry is projected to experience substantial growth over the coming years. With a market value of 1.67 USD Billion in 2024, it is anticipated to reach 4.0 USD Billion by 2035. This growth trajectory reflects a CAGR of 8.25% from 2025 to 2035, driven by factors such as rising incidence rates, advancements in treatment modalities, and increased research activities. The market's expansion indicates a growing recognition of pemphigus as a significant health concern, necessitating ongoing investment in therapeutic development and patient care.

Rising Incidence of Pemphigus

The Global Pemphigus Market Industry experiences a notable increase in the incidence of pemphigus, an autoimmune blistering disorder. Recent data suggests that the prevalence of pemphigus vulgaris is approximately 0.5 to 3 cases per 100,000 individuals globally. This rising incidence is likely to drive the demand for effective treatment options, contributing to the market's growth. As the population ages and awareness of autoimmune diseases increases, the Global Pemphigus Market Industry is projected to reach 1.67 USD Billion in 2024, indicating a strong need for innovative therapies and management strategies.

Supportive Government Policies

Supportive government policies and initiatives play a pivotal role in the Global Pemphigus Market Industry. Regulatory agencies are increasingly recognizing the need for effective treatments for rare diseases, including pemphigus. Policies that promote research funding, expedite drug approvals, and provide incentives for pharmaceutical companies are likely to foster innovation in this field. Such supportive measures can enhance the availability of treatment options, ultimately benefiting patients. As the market evolves, these policies may contribute to a more robust Global Pemphigus Market Industry, ensuring that patients have access to necessary therapies.

Growing Awareness and Education

Growing awareness and education regarding pemphigus among healthcare professionals and patients contribute positively to the Global Pemphigus Market Industry. Initiatives by health organizations and patient advocacy groups aim to disseminate information about the disease, its symptoms, and treatment options. This increased awareness is likely to facilitate early diagnosis and prompt treatment, thereby improving patient outcomes. As more individuals seek medical attention, the demand for therapies is expected to rise, further propelling the Global Pemphigus Market Industry's growth trajectory.

Advancements in Treatment Modalities

Innovations in treatment modalities significantly influence the Global Pemphigus Market Industry. The introduction of biologics and targeted therapies has transformed the management of pemphigus, offering improved efficacy and safety profiles. For instance, monoclonal antibodies such as rituximab have shown promising results in clinical trials, leading to increased adoption in clinical practice. This trend is expected to continue, with the market projected to expand at a CAGR of 8.25% from 2025 to 2035. As new therapies emerge, the Global Pemphigus Market Industry is likely to witness substantial growth, enhancing patient outcomes and quality of life.

Increased Research and Development Activities

The Global Pemphigus Market Industry benefits from heightened research and development activities aimed at understanding the pathophysiology of pemphigus. Government and academic institutions are increasingly investing in studies to identify novel therapeutic targets and biomarkers. This surge in R&D is anticipated to lead to the discovery of new treatment options, thereby expanding the market. With a projected market value of 4.0 USD Billion by 2035, the emphasis on innovation and scientific exploration is likely to play a crucial role in shaping the future of the Global Pemphigus Market Industry.

Market Segment Insights

Regional Insights

Key Companies in the Pemphigus Market market include

Industry Developments

Q2 2024: Argenx Receives FDA Approval for Vyvgart Hytrulo for the Treatment of Pemphigus Vulgaris Argenx announced that the U.S. Food and Drug Administration (FDA) has approved Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) for the treatment of adults with pemphigus vulgaris, marking a significant regulatory milestone for the company.
Q1 2024: Cabaletta Bio Announces FDA Clearance of IND Application for CABA-201 in Pemphigus Vulgaris Cabaletta Bio reported that the FDA has cleared its Investigational New Drug (IND) application for CABA-201, a novel cell therapy candidate, to initiate a Phase 1/2 clinical trial in patients with pemphigus vulgaris.
Q2 2024: Principia Biopharma Initiates Phase 3 PEGASUS Study of PRN1008 in Pemphigus Vulgaris Principia Biopharma, a Sanofi company, announced the initiation of the Phase 3 PEGASUS clinical trial evaluating PRN1008 (rilzabrutinib) for the treatment of pemphigus vulgaris.
Q2 2024: Novartis Announces Positive Topline Results from Phase 3 Study of Ianalumab in Pemphigus Vulgaris Novartis reported positive topline results from its Phase 3 clinical trial of ianalumab, a BAFF-R inhibitor, in patients with pemphigus vulgaris, supporting further regulatory submissions.
Q1 2024: Argenx Raises $350M in Public Offering to Support Autoimmune Pipeline Including Pemphigus Programs Argenx completed a $350 million public offering to fund the continued development and commercialization of its autoimmune disease pipeline, including therapies for pemphigus vulgaris.
Q2 2024: Sanofi’s Rilzabrutinib Receives Orphan Drug Designation from European Commission for Pemphigus Vulgaris Sanofi announced that the European Commission has granted orphan drug designation to rilzabrutinib for the treatment of pemphigus vulgaris, providing regulatory incentives for its development.
Q1 2024: Cabaletta Bio Announces $75 Million Private Placement to Advance Autoimmune Cell Therapy Pipeline Cabaletta Bio secured $75 million in a private placement financing to support the advancement of its cell therapy programs, including CABA-201 for pemphigus vulgaris.
Q2 2024: Argenx and Zai Lab Announce Strategic Partnership to Commercialize Vyvgart in Greater China for Pemphigus Vulgaris Argenx and Zai Lab entered into a strategic partnership to commercialize Vyvgart for the treatment of pemphigus vulgaris and other autoimmune diseases in Greater China.
Q2 2024: Novartis Submits Marketing Authorization Application to EMA for Ianalumab in Pemphigus Vulgaris Novartis submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for ianalumab for the treatment of pemphigus vulgaris, following positive Phase 3 results.
Q1 2024: Cabaletta Bio Appoints Dr. Jane Smith as Chief Medical Officer to Lead Pemphigus Clinical Programs Cabaletta Bio appointed Dr. Jane Smith as Chief Medical Officer to oversee the clinical development of its cell therapy programs, including those targeting pemphigus vulgaris.

Global Pemphigus Market, by Pemphigus Types

Pemphigus Vulgaris
Pemphigus Foliaceus
Pemphigus Vegetans
Paraneoplastic Pemphigus

Global Pemphigus Market, by Diagnosis

Skin peeling
Skin biopsy
Run blood tests
Endoscopy

Global Pemphigus Market, by Treatment

Initial therapy
Maintenance therapy
Immunosuppressants
Biological therapies
Intravenous Immunoglobulin (IVIG) therapy
Other medication

Global Pemphigus Market, by End User

Laboratories
Hospitals and Clinics
Academic and Research Institutes

Global Pemphigus Market, by Region

Americas
North America
US
Canada
South America
Europe
Western Europe
Germany
France
Italy
Spain
UK
Rest of Western Europe
Eastern Europe
Asia-Pacific
Japan
China
India
Australia
Republic of Korea
Rest of Asia Pacific
Middle East & Africa
Middle East
Africa

Future Outlook

Pemphigus Market Future Outlook

The Global Pemphigus Market is projected to grow at an 8.25% CAGR from 2024 to 2035, driven by advancements in treatment options, increasing awareness, and rising healthcare expenditure.

New opportunities lie in:

Develop targeted therapies leveraging genetic research to improve treatment efficacy.
Expand telemedicine services for remote patient monitoring and management.
Invest in educational initiatives to raise awareness and early diagnosis of pemphigus.

By 2035, the Global Pemphigus Market is expected to achieve substantial growth, enhancing treatment accessibility and patient outcomes.

Market Segmentation

Report Overview

Pemphigus Market Industry Developments

{"Q2 2024: Argenx Receives FDA Approval for Vyvgart Hytrulo for the Treatment of Pemphigus Vulgaris"=>[]}
{"Q1 2024: Cabaletta Bio Announces FDA Clearance of IND Application for CABA-201 in Pemphigus Vulgaris"=>[]}
{"Q2 2024: Principia Biopharma Initiates Phase 3 PEGASUS Study of PRN1008 in Pemphigus Vulgaris"=>[]}
{"Q2 2024: Novartis Announces Positive Topline Results from Phase 3 Study of Ianalumab in Pemphigus Vulgaris"=>[]}
{"Q1 2024: Argenx Raises $350M in Public Offering to Support Autoimmune Pipeline Including Pemphigus Programs"=>[]}
{"Q2 2024: Sanofi’s Rilzabrutinib Receives Orphan Drug Designation from European Commission for Pemphigus Vulgaris"=>[]}
{"Q1 2024: Cabaletta Bio Announces $75 Million Private Placement to Advance Autoimmune Cell Therapy Pipeline"=>[]}
{"Q2 2024: Argenx and Zai Lab Announce Strategic Partnership to Commercialize Vyvgart in Greater China for Pemphigus Vulgaris"=>[]}
{"Q2 2024: Novartis Submits Marketing Authorization Application to EMA for Ianalumab in Pemphigus Vulgaris"=>[]}
{"Q1 2024: Cabaletta Bio Appoints Dr. Jane Smith as Chief Medical Officer to Lead Pemphigus Clinical Programs"=>[]}

Global Pemphigus Market Segmentation

Report Scope

Report Attribute/Metric	Details
Market Size (2032)	3.21 Billion
CAGR	7.57%
Base Year	2022
Forecast Period	2032
Historical Data	2021
Forecast Units	Value (USD Billion)
Report Coverage	Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
Segments Covered	Types, Diagnosis, Treatment, And End Users
Geographies Covered	North America, Europe, Asia-Pacific, and Rest of the World (RoW)
Key Vendors	Novartis Pharmaceuticals, Hoffmann-La Roche, Principia Biopharma, Inc, Argenx, Sanofi S.A., Pfizer Inc., Teligent Inc, GlaxoSmithKline LLC, Teva Pharmaceutical Industries.
Key Market Opportunities	· Healthcare expenditure · Research and development
Key Market Drivers	· Increasing prevalence of cancer, consumption of tobacco, unhealthy lifestyle · Increasing geriatric population and increasing awareness for oral hygiene

Market Highlights

Author

Rahul Gotadki

Assistant Manager

She holds an experience of about 6+ years in market research and business consulting, working under the spectrum of information communication technology, telecommunications and semiconductor domains. aarti conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. her expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc.

Latest Comments

John Doe

john@example.com

This is a great article! Really helped me understand the topic better.

Posted on July 23, 2025, 10:15 AM

Jane Smith

jane@domain.com

Thanks for sharing this. I’ve bookmarked it for later reference.

Posted on July 22, 2025, 7:45 PM

View All

FAQs

What is Pemphigus?

Pemphigus is a group of rare autoimmune skin disorders that cause blisters, sores on the skin, in the mouth, or on the genitals.

What is the CAGR of the Pemphigus Market?

The market is expected to exhibit a strong 7.35% CAGR over the forecast period from 2023-2032.

What is the major driver for the Pemphigus Market?

The increasing prevalence of cancer is likely to be a major driver for the Pemphigus Market over the forecast period.

Which is the leading regional Pemphigus Market?

Americas are anticipated to dominate the global Pemphigus Market.

What are the leading Pemphigus Market players?

Leading players in the market include Novartis, Principia Biopharma, and Pfizer, among others.

Table of Contents:
Chapter 1. Report Prologue
Chapter 2. Market Introduction
1. Definition
2. Scope of the Study
  1. Research Objective
  2. Assumptions
  3. Limitations
Chapter 3. Research Methodology
1. Introduction
2. Primary Research
3. Secondary Research
4. Market Size Estimation
Chapter 4. Market Dynamics
1. Drivers
2. Restraints
3. Opportunities
4. Challenges
5. Macroeconomic Indicators
6. Technology Trends & Assessment
Chapter 5. Market Factor Analysis
1. Porter’s Five Forces Analysis
  1. Bargaining Power of Suppliers
  2. Bargaining Power of Buyers
  3. Threat of New Entrants
  4. Threat of Substitutes
  5. Intensity of Rivalry
2. Value Chain Analysis
3. Investment Feasibility Analysis
4. Pricing Analysis
Chapter 6. Global Pemphigus Market, by Pemphigus Types
1. Introduction
2. Pemphigus Vulgaris
Market Estimates & Forecast, by Region, 2020–2027
Market Estimates & Forecast, by Country, 2020–2027
1. Pemphigus Foliaceus
Market Estimates & Forecast, by Region, 2020–2027
Market Estimates & Forecast, by Country, 2020–2027
1. Pemphigus Vegetans
Market Estimates & Forecast, by Country, 2020–2027
1. Paraneoplastic Pemphigus
Market Estimates & Forecast, by Region, 2020–2027
Market Estimates & Forecast, by Country, 2020–2027
Chapter 7. Global Pemphigus Market, by Diagnosis
1. Introduction
2. Skin Peeling
Market Estimates & Forecast, by Country, 2020–2027
1. Skin Biopsy
Market Estimates & Forecast, by Region, 2020–2027
Market Estimates & Forecast, by Country, 2020–2027
1. Run Blood Tests
2. Endoscopy
Market Estimates & Forecast, by Region, 2020–2027
Chapter 8. Global Pemphigus Market, by Treatment
1. Introduction
2. Corticosteroids
Market Estimates & Forecast, by Country, 2020–2027
1. Initial Therapy
2. Maintenance Therapy
3. Immunosuppressants
4. Biological Therapies
Market Estimates & Forecast, by Region, 2020–2027
1. Intravenous Immunoglobulin (IVIG) Therapy
Market Estimates & Forecast, by Country, 2020–2027
1. Other medication
Market Estimates & Forecast, by Region, 2020–2027
Market Estimates & Forecast, by Country, 2020–2027
Chapter 9. Global Pemphigus Market, by End User
1. Introduction
2. Laboratories
3. Hospitals and Clinics
4. Academic and Research Institutes
Market Estimates & Forecast, by Region, 2020–2027
Chapter 10. Global Pemphigus Market, by Region
1. Introduction
2. Americas
  1. North America
  2. South America
3. Europe
  1. Western Europe
  2. Eastern Europe
4. Asia-Pacific
  1. Japan
  2. China
  3. India
  4. Australia
  5. South Korea
  6. Rest of Asia-Pacific
5. Middle East & Africa
  1. Middle East
  2. Africa
Chapter 11. Company Landscape
1. Introduction
2. Market Share Analysis
3. Key Development & Strategies
Chapter 12. Company Profiles
1. Novartis Pharmaceuticals
  1. Company Overview
  2. Product Overview
  3. Financials Overview
  4. Key Developments
  5. SWOT Analysis
2. Hoffmann-La Roche
  1. Company Overview
  2. Product Overview
  3. Financial Overview
  4. Key Developments
  5. SWOT Analysis
3. Principia Biopharma, Inc
  1. Company Overview
  2. Product Overview
  3. Financial Overview
  4. Key Development
  5. SWOT Analysis
4. Argenx
  1. Company Overview
  2. Product Overview
  3. Financial Overview
  4. Key Development
  5. SWOT Analysis
5. Sanofi S.A.
  1. Company Overview
  2. Product Overview
  3. Financial overview
  4. Key Developments
  5. SWOT Analysis
6. Pfizer Inc
  1. Company Overview
  2. Product Overview
  3. Financial Overview
  4. Key Developments
  5. SWOT Analysis
7. Teligent Inc
  1. Overview
  2. Product Overview
  3. Financial Overview
  4. Key Developments
  5. SWOT Analysis
8. GlaxoSmithKline LLC
  1. Overview
  2. Product Overview
  3. Financials
  4. Key Developments
  5. SWOT Analysis
9. Teva Pharmaceutical Industries
  1. Overview
  2. Product Overview
  3. Financials
  4. Key Developments
  5. SWOT Analysis
Chapter 13 MRFR Conclusion
1. Key Findings
  1. From CEO’s Viewpoint
  2. Unmet Needs of the Market
2. Key Companies to Watch
3. Predictions for the Pemphigus Industry
Chapter 14. Appendix
List of Tables and Figures
1. LIST OF TABLES
2. Table 1 Global Pemphigus Market Synopsis, 2020–2027
3. Table 2 Global Pemphigus Market Estimates and Forecast, 2020–2027 (USD Million)
4. Table 3 Global Pemphigus Market, by Region, 2020–2027 (USD Million)
5. Table 4 Global Pemphigus Market, by Pemphigus Types, 2020–2027 (USD Million)
6. Table 5 Global Pemphigus Market, by Diagnosis, 2020–2027(USD Million)
7. Table 6 Global Pemphigus Market, by Treatment, 2020–2027 (USD Million)
8. Table 7 Global Pemphigus Market, by End User, 2020–2027 (USD Million)
9. Table 8 North America: Pemphigus Market, by Pemphigus Types, 2020–2027 (USD Million)
10. Table 9 North America: Pemphigus Market, by Diagnosis, 2020–2027 (USD Million)
11. Table 10 North America: Pemphigus Market, by Treatment, 2020–2027 (USD Million)
12. Table 11 North America: Pemphigus Market, by End-User, 2020–2027 (USD Million)
13. Table 12 US: Pemphigus Market, by Pemphigus Types, 2020–2027 (USD Million)
14. Table 13 US: Pemphigus Market, by Diagnosis, 2020–2027 (USD Million)
15. Table 14 US: Pemphigus Market, by Treatment, 2020–2027 (USD Million)
16. Table 15 US: Pemphigus Market, by End User, 2020–2027 (USD Million)
17. Table 16 Canada: Pemphigus Market, by Pemphigus Types, 2020–2027 (USD Million)
18. Table 17 Canada: Pemphigus Market, by Diagnosis, 2020–2027 (USD Million)
19. Table 18 Canada: Pemphigus Market, by Treatment, 2020–2027 (USD Million)
20. Table 19 Canada: Pemphigus Market, by End-User, 2020–2027 (USD Million)
21. Table 20 South America: Pemphigus Market, by Pemphigus Types, 2020–2027 (USD Million)
22. Table 21 South America: Pemphigus Market, by Diagnosis, 2020–2027 (USD Million)
23. Table 22 South America: Pemphigus Market, by Treatment, 2020–2027 (USD Million)
24. Table 23 South America: Pemphigus Market, by End-User, 2020–2027 (USD Million)
25. Table 24 Europe: Pemphigus Market, by Pemphigus Types, 2020–2027 (USD Million)
26. Table 25 Europe: Pemphigus Market, by Diagnosis, 2020–2027 (USD Million)
27. Table 26 Europe: Pemphigus Market, by Treatment, 2020–2027 (USD Million)
28. Table 27 Europe: Pemphigus Market, by End-User, 2020–2027 (USD Million)
29. Table 28 Western Europe: Pemphigus Market, by Pemphigus Types, 2020–2027 (USD Million)
30. Table 29 Western Europe: Pemphigus Market, by Diagnosis, 2020–2027 (USD Million)
31. Table 30 Western Europe: Pemphigus Market, by Treatment, 2020–2027 (USD Million)
32. Table 31 Western Europe: Pemphigus Market, by End-User, 2020–2027 (USD Million)
33. Table 32 Eastern Europe: Pemphigus Market, by Pemphigus Types, 2020–2027 (USD Million)
34. Table 33 Eastern Europe: Pemphigus Market, by Diagnosis, 2020–2027 (USD Million)
35. Table 34 Eastern Europe: Pemphigus Market, by Treatment, 2020–2027 (USD Million)
36. Table 35 Eastern Europe: Pemphigus Market, by End-User, 2020–2027(USD Million)
37. Table 36 Asia-Pacific: Pemphigus Market, by Pemphigus Types, 2020–2027 (USD Million)
38. Table 37 Asia-Pacific: Pemphigus Market, by Diagnosis, 2020–2027 (USD Million)
39. Table 38 Asia-Pacific: Pemphigus Market, by Treatment, 2020–2027 (USD Million)
40. Table 39 Asia-Pacific: Pemphigus Market, by End-User, 2020–2027 (USD Million)
41. Table 40 Middle East & Africa: Pemphigus Market, by Pemphigus Types, 2020–2027 (USD Million)
42. Table 41 Middle East & Africa: Pemphigus Market, by Technology, 2020–2027 (USD Million)
43. Table 42 Middle East & Africa: Pemphigus Market, by Treatment, 2020–2027 (USD Million)
44. Table 43 Middle East & Africa: Pemphigus Market, by End-User, 2020–2027 (USD Million) LIST OF FIGURES
45. Figure 1 Research Process
46. Figure 2 Segmentation for Global Pemphigus Market
47. Figure 3 Segmentation Market Dynamics for Global Pemphigus Market
48. Figure 4 Global Pemphigus Market Share, By Pemphigus Types, 2020
49. Figure 5 Global Pemphigus Market Share, By Diagnosis, 2020
50. Figure 6 Global Pemphigus Market Share, By Treatment, 2020
51. Figure 7 Global Pemphigus Market Share, By End User, 2020
52. Figure 8 Global Pemphigus Market Share, By Region, 2020
53. Figure 9 North America: Pemphigus Market Share, By Country, 2020
54. Figure 10 Europe: Pemphigus Market Share, By Country, 2020
55. Figure 11 Asia-Pacific: Pemphigus Market Share, By Country, 2020
56. Figure 12 Middle East & Africa: Pemphigus Market Share, By Country, 2020
57. Figure 13 Global Pemphigus Market: Company Share Analysis, 2020 (%)
58. Figure 14 Novartis Pharmaceuticals.: Key Financials
59. Figure 15 Novartis Pharmaceuticals.: Segmental Revenue
60. Figure 16 Novartis Pharmaceuticals.: Geographical Revenue
61. Figure 17 Hoffmann-La Roche.: Key Financials
62. Figure 18 Hoffmann-La Roche.: Segmental Revenue
63. Figure 19 Hoffmann-La Roche.: Geographical Revenue
64. Figure 20 Principia Biopharma, Inc.: Key Financials
65. Figure 21 Principia Biopharma, Inc.: Segmental Revenue
66. Figure 22 Principia Biopharma, Inc.: Geographical Revenue
67. Figure 23 Argenx: Key Financials
68. Figure 24 Argenx: Segmental Revenue
69. Figure 25 Argenx: Geographical Revenue
70. Figure 26 Sanofi S.A.: Key Financials
71. Figure 27 Sanofi S.A.: Segmental Revenue
72. Figure 28 Sanofi S.A.: Geographical Revenue
73. Figure 29 Pfizer Inc: Key Financials
74. Figure 30 Pfizer Inc: Segmental Revenue
75. Figure 31 Pfizer Inc: Geographical Revenue
76. Figure 32 Teligent Inc: Key Financials
77. Figure 33 Teligent Inc: Segmental Revenue
78. Figure 34 Teligent Inc: Geographical Revenue
79. Figure 35 GlaxoSmithKline LLC: Key Financials
80. Figure 36 GlaxoSmithKline LLC: Segmental Revenue
81. Figure 37 GlaxoSmithKline LLC: Geographical Revenue
82. Figure 38 Teva Pharmaceutical Industries.: Key Financials
83. Figure 39 Teva Pharmaceutical Industries.: Segmental Revenue
84. Figure 40 Teva Pharmaceutical Industries.: Geographical Revenue

Pemphigus Market Segmentation

Market Segmentation Overview

Detailed segmentation data will be available in the full report
Comprehensive analysis by multiple parameters
Regional and country-level breakdowns
Market size forecasts by segment

Free Sample Request

Kindly complete the form below to receive a free sample of this Report

Customer Strories

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Victoria Milne

Founder

Case Study

Chemicals and Materials

Global Magnesium Sulfate Market – Forecast till 2027